Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | +0.59% | -26.29% | -8.06% |
Apr. 22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
Apr. 12 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.93M |
---|---|---|---|---|---|
Net income 2024 * | -6M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.86
x | P/E ratio 2025 * |
-1.07
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.96% |
1 day | +0.59% | ||
1 week | -26.29% | ||
Current month | +28.57% | ||
1 month | +0.59% | ||
3 months | +35.71% | ||
6 months | -18.57% | ||
Current year | -8.06% |
Managers | Title | Age | Since |
---|---|---|---|
Bankole Johnson
FOU | Founder | 64 | 10-10-31 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Joseph Truluck
DFI | Director of Finance/CFO | 46 | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jack W. Reich
LAW | General Counsel | - | 20-05-18 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Tony Goodman
COO | Chief Operating Officer | 60 | 17-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.71 | +0.59% | 152,160 |
24-04-23 | 1.7 | -10.53% | 440,090 |
24-04-22 | 1.9 | -1.55% | 2,514,202 |
24-04-19 | 1.93 | -11.06% | 323,946 |
24-04-18 | 2.17 | -6.47% | 153,625 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.06% | 6.93M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ADIL Stock